Canada's government has commissioned an order worth USD 31.2m at Danish biotech company Bavarian Nordic, according to a Monday press release from the firm.
Bavarian Nordic has collaborated with Canada on the smallpox vaccine for some years. In this country, the vaccine has the name Imvamune. In the US, the vaccine is approved as Jynneos. Bavarian Nordic CEO Paul Chaplin is highly satisfied with the new order.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.